BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors

Comprehensive tumor analysis identifies potential new antibody-drug conjugate targets for hard-to-treat cancers.

Mar. 31, 2026 at 5:13pm

Got story updates? Submit your updates here. ›

A highly abstract, geometric painting in soft blues, greens, and oranges, featuring sweeping arcs, concentric circles, and precise botanical spirals, conveying the complex structural order of cancer genomics without any text or identifiable elements.Advanced tumor profiling uncovers new molecular targets for targeted cancer therapies.Waltham Today

BostonGene, a leading developer of AI-powered tumor analysis technology, announced findings from its FEASY study that used advanced RNA transcriptome profiling to identify new potential targets for antibody-drug conjugates (ADCs) in patients with advanced solid tumors. The study analyzed comprehensive genomic and transcriptomic data to uncover novel therapeutic opportunities for these difficult-to-treat cancers.

Why it matters

The discovery of new ADC targets is significant, as these targeted therapies have shown promise in treating solid tumors that are resistant to standard chemotherapies. Identifying additional options for patients with advanced cancers could lead to improved outcomes and quality of life.

The details

The FEASY study leveraged BostonGene's AI-powered tumor analysis platform to perform deep RNA sequencing on tumor samples from patients with a variety of advanced solid tumors. The analysis revealed new gene expression patterns and molecular signatures that could serve as targets for ADC development, expanding the potential therapeutic arsenal against these aggressive cancers.

  • The FEASY study was conducted between January 2025 and March 2026.

The players

BostonGene

A developer of AI-powered tumor analysis technology that provides comprehensive genomic and transcriptomic profiling of cancer samples.

Got photos? Submit your photos here. ›

What’s next

BostonGene plans to further investigate the FEASY study findings and explore potential partnerships to advance the development of new ADC therapies targeting the identified molecular signatures.

The takeaway

The FEASY study demonstrates the power of comprehensive tumor analysis using advanced genomic and transcriptomic profiling to uncover novel therapeutic targets for hard-to-treat solid tumors, potentially leading to new treatment options for patients with limited options.